Mojgan Zarif

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency

M. Minden, E. Atenafu, J. Capo-Chichi, 2022, Cancer medicine.

NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.

M. Minden, E. Atenafu, J. Capo-Chichi, 2022, Leukemia research.

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation

M. Minden, E. Atenafu, J. Capo-Chichi, 2023, Cancers.

Impact of secondary‐type mutations in NPM1 mutated AML

Y. W. Yeung, Qianghua Zhou, Hong Chang, 2023, European journal of haematology.

AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.

Y. W. Yeung, M. Minden, E. Atenafu, 2023, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.